Related Experiment Video
Updated: Jun 3, 2026
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
Risa Maeda1, Chiharu Tabata, Rie Tabata
1Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Abstract:
Malignant pleural mesothelioma (MPM), an asbestos-related aggressive malignant tumor of mesothelial origin, shows limited response to therapy and overall survival remains very poor. Reactive oxygen species play an important role in asbestos toxicity. Here, we found that the patients with MPM had significantly higher serum levels of thioredoxin-1 (TRX) than control population. The patients with advanced-stage MPM showed higher levels of TRX than those with early-stage MPM. The difference in overall survival between the groups with lower and higher serum TRX levels was significant. Our data suggest that serum TRX concentration could be a useful clinical marker for MPM.
Insights
Serum thioredoxin-1 (TRX) levels are higher in malignant pleural mesothelioma (MPM) patients. Higher TRX indicates advanced cancer and poorer survival, suggesting TRX as a potential biomarker for this asbestos-related cancer.
Area of Science:
- Oncology
- Biochemistry
- Environmental Health
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related cancer with poor therapeutic response and survival.
- Reactive oxygen species are implicated in asbestos-induced toxicity.
Purpose of the Study:
- To investigate serum thioredoxin-1 (TRX) levels in patients with MPM.
- To evaluate the correlation between serum TRX levels and MPM stage and patient survival.
Main Methods:
- Serum samples were collected from patients with MPM and a control population.
- Serum thioredoxin-1 (TRX) concentrations were measured.
- Statistical analysis was performed to compare TRX levels between groups and correlate with clinical parameters.
Main Results:
- Patients with MPM exhibited significantly higher serum TRX levels compared to the control group.
- Serum TRX levels were elevated in patients with advanced-stage MPM compared to early-stage MPM.
- A significant difference in overall survival was observed between patients with lower and higher serum TRX levels.
Conclusions:
- Serum thioredoxin-1 (TRX) is significantly elevated in patients with malignant pleural mesothelioma.
- Serum TRX levels correlate with disease stage and overall survival in MPM patients.
- Serum TRX concentration represents a potential clinical biomarker for MPM diagnosis and prognosis.
